Syngene to approach regulators for Mangalore unit audit in 12-18 months
As startups mushroom in drug R&D, Syngene builds CRO muscle
Biologics Testing Highlights Need for Analytical Skills
We are co-innovating with global pharma companies – Syngene MD & CEO
Manufacturing vaccines during Covid-19: CMOs/CDMOs to the rescue
Seeing good demand for biologics manufacturing- Syngene CEO Jonathan Hunt
Scientific breadth-depth of our portfolio contributing to developmentof new therapies- Mahesh Bhalgat
Syngene CEO on what sets Indian CROs apart
Syngene client Dyadic announces development of COVID-19 vaccine in India
Syngene’s client Panbela announces issuance of key U.S. patent for pancreatic cancer
